Post-polycythemia vera myelofibrosis (PPV-MF) - Pipeline Review, H2 2012

Global Markets Direct, September 2012, Pages: 50

Post-polycythemia vera myelofibrosis (PPV-MF) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Post-polycythemia vera myelofibrosis (PPV-MF) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Post-polycythemia vera myelofibrosis (PPV-MF), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post-polycythemia vera myelofibrosis (PPV-MF). Post-polycythemia vera myelofibrosis (PPV-MF) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Post-polycythemia vera myelofibrosis (PPV-MF).
- A review of the Post-polycythemia vera myelofibrosis (PPV-MF) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Post-polycythemia vera myelofibrosis (PPV-MF) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Post-polycythemia vera myelofibrosis (PPV-MF).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Post-polycythemia vera myelofibrosis (PPV-MF) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Post-polycythemia vera myelofibrosis (PPV-MF) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Post-polycythemia vera myelofibrosis (PPV-MF) 7
Post-polycythemia vera myelofibrosis (PPV-MF) Therapeutics under Development by Companies 9
Post-polycythemia vera myelofibrosis (PPV-MF) Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Post-polycythemia vera myelofibrosis (PPV-MF) Therapeutics – Products under Development by Companies 14
Post-polycythemia vera myelofibrosis (PPV-MF) Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Post-polycythemia vera myelofibrosis (PPV-MF) Therapeutics Development 16
Sanofi-Aventis 16
AstraZeneca PLC 17
Gilead Sciences, Inc. 18
YM BioSciences Inc. 19
Incyte Corporation 20
PharmaMar, S.A. 21
Post-polycythemia vera myelofibrosis (PPV-MF) – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
AZD-1480 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
momelotinib - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ruxolitinib - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
SAR-302503 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
plitidepsin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
GS-6624 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
GC-1008 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Post-polycythemia vera myelofibrosis (PPV-MF) Therapeutics – Drug Profile Updates 37
Post-polycythemia vera myelofibrosis (PPV-MF) Therapeutics - Dormant Products 45
Post-polycythemia vera myelofibrosis (PPV-MF) – Product Development Milestones 46
Featured News & Press Releases 46
Jun 04, 2012: Incyte Presents New Clinical Data Of Jakafi At ASCO 2012 Annual Meeting 46
May 16, 2012: Sanofi To Present Data On SAR302503 At 2012 American Society Of Clinical Oncology Annual Meeting 47
Apr 20, 2012: Incyte Announces EU Regulatory Milestone From Novartis For Ruxolitinib 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50

List of Tables
Number of Products Under Development for Post-polycythemia vera myelofibrosis (PPV-MF), H2 2012 7
Products under Development for Post-polycythemia vera myelofibrosis (PPV-MF) – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Sanofi-Aventis, H2 2012 16
AstraZeneca PLC, H2 2012 17
Gilead Sciences, Inc., H2 2012 18
YM BioSciences Inc., H2 2012 19
Incyte Corporation, H2 2012 20
PharmaMar, S.A., H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Post-polycythemia vera myelofibrosis (PPV-MF) Therapeutics – Drug Profile Updates 37
Post-polycythemia vera myelofibrosis (PPV-MF) Therapeutics – Dormant Products 45

List of Figures
Number of Products under Development for Post-polycythemia vera myelofibrosis (PPV-MF), H2 2012 7
Products under Development for Post-polycythemia vera myelofibrosis (PPV-MF) – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Customers who bought this item also bought

• Essential Thrombocythemia – Pipeline Review, H1 2013
• Post Operative Nausea And Vomiting – Pipeline Review, H1 2013
• Myeloproliferative Disorders. Biology and Management
• Nausea – Pipeline Review, H1 2013
• Alzheimer's Disease – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013
• Diabetes Diagnostics - Global Strategic Business Report
• Liver Transplantation – Pipeline Review, H1 2013